1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2016

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, “Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2016" provides an overview of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Familial Hypercholesterolemia (Type II Hyperlipoproteinemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2016
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials 19
Clinical Trials by Phase in E7 Countries 21
Clinical Trials in E7 Countries by Trial Status 22
Clinical Trials by Phase 23
In Progress Trials by Phase 24
Clinical Trials by Trial Status 25
Clinical Trials by End Point Status 26
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials 30
Prominent Drugs 32
Latest Clinical Trials News on Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) 33
Jun 28, 2016: Two Additional Phase 3 Lipid-Lowering Studies of Bococizumab Deliver Positive Topline Results 33
Clinical Trial Profile Snapshots 35
Appendix 189
Abbreviations 189
Definitions 189
Research Methodology 190
Secondary Research 190
About GlobalData 191
Contact Us 191
Disclaimer 191
Source 192

List of Tables
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Region, 2016* 6
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, North America, Top Countries, 2016* 12
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 13
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 14
Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2016* 16
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 17
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 18
Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2016* 20
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 21
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 22
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Phase, 2016* 23
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 24
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 25
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 26
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 27
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 28
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 29
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 31
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 32

List of Figures
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 13
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 14
Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2016* 15
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 17
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 18
Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2016* 19
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 21
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 22
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 23
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 24
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 25
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 26
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 27
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 28
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 29
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 30
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 32
GlobalData Methodology 190

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The global clinical trial management system (CTMS) market is estimated to grow at a CAGR of 11.5% from 2016 to 2021, to reach USD 920.0 billion by 2021. The adoption of CTMS software is on the rise across ...

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global CRO services market is estimated to grow at a CAGR of 7.4% from 2016 to 2021, to reach USD 41.86 billion by 2021 from USD 29.29 billion in 2016. Growth in this market is primarily attributed ...

Clinical Trial Management System (CTMS) - Global Market Outlook (2016-2022)

Clinical Trial Management System (CTMS) - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • November 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Clinical Trial Management System (CTMS) market is expected to grow from $493.58 million in 2015 to reach $1118.58 million by 2022 with a CAGR of 12.4%. Huge research ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.